High-dose gamma-globulin therapy for nephrotic membranous nephropathy patients

High-dose gamma-globulin therapy for nephrotic membranous nephropathy patients - HIGHNESS study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006939

Enrollment

100

Registered

2012-01-30

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

membranous nephropathy, nephrotic syndrome

Interventions

Immunoglobulin ARB or ACEi with or without Statin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Nephrotic membranous nephropathy

Exclusion criteria

Exclusion criteria: Secondary membranous nephropathy Diabetic patients Recent cardiovascular accidents within 6 months Malignancy Liver diseases Patients treated with immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
Remission rate of complete or incomplete type 1	—

Secondary

Measure	Time frame
Alteration of proteinuria or renal function Compliction of infectious diseases or cardiovascular diseases Spontaneous remission rate in natural clinical course	—

Countries

Japan

Contacts

Public ContactHitoshi Yokoyama

Kanazawa Medical University Hospital Nephrology

h-yoko@kanazawa-med.ac.jp076-286-2211(3401)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026